Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.45 |
| ▸ | HTR7 | P34969 | 9/20 | 0.45 |
| ▸ | HTR6 | P50406 | 9/20 | 0.45 |
| ▸ | HTR1A | P08908 | 7/20 | 0.45 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | HTR2A | P28223 | 7/20 | 0.45 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237973 | 0.78 | HTR3A (0.46) | — | |
| SCHEMBL239514 | 0.77 | HRH3 (0.45) | HTR7HTR6HTR1A | |
| SCHEMBL239284 | 0.76 | CYP11B1 (0.52) | CYP11B1CYP11B2HTR7HTR6HTR1A | |
| SCHEMBL239296 | 0.74 | ACHE (0.39) | HTR1ADRD2 | |
| SCHEMBL238126 | 0.73 | HTR3E (0.45) | HTR1AHTR2A | |
| SCHEMBL1728859 | 0.72 | CYP11B2 (0.48) | CYP11B1CYP11B2HTR7HTR6HTR1A | |
| SCHEMBL238635 | 0.71 | HTR1A (0.48) | HTR7HTR6HTR1ADRD2HTR2A | |
| SCHEMBL240217 | 0.69 | ACHE (0.37) | HTR1ADRD2 | |
| SCHEMBL240154 | 0.69 | HRH4 (0.47) | HTR1A | |
| SCHEMBL238634 | 0.69 | CHRM5 (0.40) | HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
| EP-1633735-B1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI SA (FR) | 2011-11-30 | — | — | EP | disclosed |
| US-8034818-B2 | Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| US-20060089344-A1 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | US | disclosed |
| EP-1633735-A1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004099176-A1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089344-A1 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | CLCN2, CNR2, RCC2 | CYP11B1 2137/4885CYP11B2 1177/4885HTR7 2151/4885 |
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP11B1 1758/4885CYP11B2 1039/4885HTR7 1614/4885 |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, H1-2 | CYP11B1 1213/4885CYP11B2 656/4885HTR7 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.